Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,343 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the transaction, the insider now owns 165,254 shares in the company, valued at approximately $4,941,094.60. This trade represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.41, for a total value of $47,738.99.
• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.50, for a total value of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total value of $34,354.25.

Hims & Hers Health Stock Down 2.2 %

Shares of NYSE HIMS opened at $30.67 on Wednesday. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $31.68. The business has a 50-day simple moving average of $20.85 and a two-hundred day simple moving average of $19.44. The company has a market cap of $6.70 billion, a P/E ratio of 69.69 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

HIMS has been the subject of several research analyst reports. TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $20.71.

Institutional Trading of Hims & Hers Health

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares during the last quarter. Renaissance Technologies LLC lifted its position in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. State Street Corp lifted its position in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after buying an additional 206,078 shares during the last quarter. Geode Capital Management LLC lifted its position in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.